Coherus BioSciences

Develops and commercializes biosimilars for healthcare

Redwood City, California, United States

About Coherus BioSciences

Coherus BioSciences develops and sells biosimilars, which are highly similar versions of approved biologic medicines used to treat various diseases. These biosimilars are designed to be as effective and safe as the original products but are offered at a lower cost, making them more affordable for patients and healthcare systems. The company focuses on research, development, and commercialization of these products, ensuring they meet strict regulatory standards for quality and efficacy. Coherus aims to improve patient lives by expanding access to essential biologic treatments, thereby addressing the rising costs of healthcare. Their business model allows them to generate revenue through the sale of these cost-effective alternatives, giving them a competitive advantage in the biopharmaceutical market.

Redwood City, CaliforniaHeadquarters
2010Year Founded
$114.5MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees

Benefits

Competitive base salary
Target bonus based on performance
stock options
Medical, dental, & vision coverage
PTO
401(k) plan
FSA

Risks

Sandoz acquisition of Coherus' assets may lead to market share erosion.
30% staff reduction could impact operational efficiency and product development.
Divestment of Canadian rights to Toripalimab limits revenue potential in Canada.

Differentiation

Coherus focuses on cost-effective biosimilars for oncology and inflammatory diseases.
The company leverages advanced process science and analytical characterization in development.
Coherus' Udenyca wearable injector offers innovative drug delivery for pegfilgrastim.

Upsides

Global biosimilars market projected to grow at 24.7% CAGR from 2023 to 2030.
FDA guidance on biosimilar interchangeability could boost market acceptance for Coherus.
Collaborations with research institutes enhance development of novel therapies.

Funding

Total raised$114.49 M
Latest valuation$300.00 M
StageIPO
POST IPO DEBT
12/31/2021
$100
IPO
10/31/2014
$85
$300.00 M
SERIES C
4/30/2014
$55
$273.50 M
DEBT
6/30/2013
$28
SERIES A
2/28/2011
$2
$7.50 M